Seizures associated with venlafaxine, methylphenidate, and zolpidem.
Sirpa A
SA
Tavakoli
Ondria C
OC
Gleason
D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000627:therapeutic use; D015897:Comorbidity; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects* / Q000627:therapeutic use; D008774:Methylphenidate / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride; D000077334:Zolpidem
D018687:Antidepressive Agents, Second-Generation; D000697:Central Nervous System Stimulants; D003511:Cyclohexanols; D006993:Hypnotics and Sedatives; D011725:Pyridines; D008774:Methylphenidate; D000069470:Venlafaxine Hydrochloride; D000077334:Zolpidem